TABLE 3.

The most common treatment-related adverse events.

	Grades 1 and 2
	All (n = 31)	Anlotinib and TMZ (n = 14)	Anlotinib (n = 17)
Hypertension, n (%)	15 (48.4)	8 (57.1)	7 (41.2)
Gastrointestinal reactions, n (%)	11 (35.5)	9 (64.3)	2 (11.8)
Leukopenia, n (%)	11 (35.5)	9 (64.3)	2 (11.8)
Anemia, n (%)	8 (25.8)	8 (57.1)	0
Oral mucositis, n (%)	7 (22.6)	4 (28.6)	3 (17.6)
Liver function impairment, n (%)	7 (22.6)	7 (50)	0
Hypertriglyceridemia, n (%)	5 (16.1)	2 (14.3)	3 (17.6)
Proteinuria, n (%)	4 (12.9)	3 (21.4)	1 (5.9)
Hand–foot reaction, n (%)	4 (12.9)	3 (21.4)	1 (5.9)
Electrocardiographic abnormality, n (%)	4 (12.9)	4 (28.6)	0
Thrombocytopenia, n (%)	3 (9.7)	3 (21.4)	0
Bleeding, n (%)	2 (6.5)	1 (7.1)	1 (5.9)
Hypothyroidism, n (%)	2 (6.5)	1 (7.1)	1 (5.9)